http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011166059-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0398cdc430a91a8870308adf1e51c603 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2009-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b3c60c3abb72dad2814f4c1df34cea3 |
| publicationDate | 2011-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2011166059-A1 |
| titleOfInvention | Means and methods for evaluating a therapy with a p38 map kinase inhibitor |
| abstract | The present invention relates to a method for determining whether therapy with a p38 MAP kinase inhibitor is potentially beneficial or potentially contraindicated for a subject suffering from a p38-mediated condition comprising measuring in a sample obtained from the subject the presence of at least one chromatin remodelling gene and/or of at least one pro-inflammatory gene, wherein the treatment is potentially beneficial for the subject, if at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition; or wherein the treatment is potentially contraindicated for the subject, if at least one chromatin remodelling gene is overrepresented and/or at least one pro-inflammatory gene is underrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. The present invention also relates to medical uses and methods of treatment applying a p38 MAP kinase inhibitor for treating a p38-mediated condition in a subject, wherein the patient is amenable to the treatment with the p38 MAP kinase inhibitor, if in the subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. Furthermore, a packaged medicament and a kit are provided comprising a p38 MAP kinase inhibitor or means for determining the presence of at least one chromatin remodelling gene and/or at least one pro-inflammatory gene in a sample from a subject suffering from a p38-mediated condition and instructions for use indicating that a subject suffering from a p38-mediated condition is amenable to the treatment with the p38 MAP kinase inhibitor, if it has been determined whether in said subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. |
| priorityDate | 2008-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 142.